To the Editor: In the study by Dr D’Amico
and colleagues1 an improvement in survival
and freedom from salvage therapy was observed with androgen suppression therapy
(AST) plus radiation therapy (RT). While there are patients who benefit from
AST under certain conditions, what still remains unclear is which patients
(intermediate- vs high-risk) should be treated with short-term (≤6 months)
AST plus RT vs long-term (>2 years) AST plus RT, and whether any AST is necessary
in the setting of RT dose escalation.
Horwitz EM, Feigenberg SJ, Pollack A, Hanks GE, Uzzo RG. Androgen Suppression Plus Radiation Therapy for Prostate Cancer. JAMA. 2004;292(17):2084–2085. doi:https://doi.org/10.1001/jama.292.17.2084-b
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: